Literature DB >> 24145709

[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma].

M Merz1, I Herth, J Brandt, M Hundemer, K Neben, H Goldschmidt, C P Heußel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24145709     DOI： 10.1007/s00063-013-0298-z

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN： 2193-6218            Impact factor:   0.840


× No keyword cloud information.
  9 in total

1.  A case of lenalidomide-induced hypersensitivity pneumonitis.

Authors:  Erika Lerch; Sandor Györik; Jonas Feilchenfeldt; Luca Mazzucchelli; Franco Quadri
Journal:  Onkologie       Date:  2010-04-13

2.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

Authors:  S Vincent Rajkumar; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; Susan M Geyer; Brian Kabat; Steven R Zeldenrust; Shaji Kumar; Philip R Greipp; Rafael Fonseca; John A Lust; Stephen J Russell; Robert A Kyle; Thomas E Witzig; Morie A Gertz
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

3.  Acute lung toxicity related to pomalidomide.

Authors:  Holly L Geyer; Robert W Viggiano; Martha Q Lacy; Tom E Witzig; Kevin O Leslie; Joseph R Mikhael; Keith Stewart
Journal:  Chest       Date:  2011-08       Impact factor: 9.410

Review 4.  [Rheumatic patients in the intensive care unit].

Authors:  P Lehmann; T Brünnler; B Salzberger; M Fleck
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-02-02       Impact factor: 0.840

5.  Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.

Authors:  Ulrike Klein; Florentina Kosely; Jens Hillengass; Michael Hundemer; Stefan Schmitt; Kai Neben; Thomas Moehler; Ute Hegenbart; Anthony D Ho; Hartmut Goldschmidt
Journal:  Ann Hematol       Date:  2008-07-31       Impact factor: 3.673

Review 6.  [Chronic critically ill patients from the perspective of hematologists/oncologists].

Authors:  T Staudinger; P Schellongowski
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-02-28       Impact factor: 0.840

7.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

8.  Pneumonitis-associated hyperprocalcitoninemia.

Authors:  E S Nylén; R H Snider; K A Thompson; P Rohatgi; K L Becker
Journal:  Am J Med Sci       Date:  1996-07       Impact factor: 2.378

9.  Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit.

Authors:  N Lehners; P Schnitzler; S Geis; J Puthenparambil; M A Benz; B Alber; T Luft; P Dreger; C Eisenbach; C Kunz; A Benner; U Buchholz; E Aichinger; U Frank; K Heeg; A D Ho; G Egerer
Journal:  Bone Marrow Transplant       Date:  2013-07-01       Impact factor: 5.483
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.